personalized treatment

  • August 23, 2022  

    Using AI and Drug Testing to Design Personalized Cancer Drug Combos

    With: Noah Berlow, PhDDiana Azzam, PhD

    Advanced cancer treatment often involves combining multiple drugs. But with a huge number of possible combinations, it is difficult to know which mix might work best for each patient. Here, our Curious Dr. George asks two leaders to describe how the company First Ascent Biomedical is addressing this challenge. Curious Dr. George: The U.S. Food and Drug Administration (FDA) has approved many thousands of… Read more »

  • September 18, 2018  

    Biomarkers, PARP Inhibitors Vital for Personalized Treatment in Breast Cancer Subtypes Bookmark

    Emma Shtivelman, PhD

    Excerpt from OncLive:

    “Developing predictive biomarkers will be key to treating patients with triple-negative breast cancer (TNBC), especially when choosing a targeted therapy, said Banu K. Arun, MD.

    “In a presentation during the 2018 OncLive® State of the Science Summit™ on Breast Cancer, Arun said there is evidence that PARP inhibitors as well as immunotherapy in combination with various agents may be effective in women with TNBC and BRCA1-related breast cancers, but the science isn’t there yet.”

    Go to full article published by OncLive on Aug 29, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.